Lilly Drops Commercialization Efforts For Yentreve
This article was originally published in The Pink Sheet Daily
A year after withdrawing its NDA, Lilly gives up on a stress urinary incontinence indication for duloxetine.
You may also be interested in...
Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.
A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.